Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-Guard
- Development stage
- Phase 2
- Lead developer
- Xenikos
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
T-Guard is a combination immunotoxin therapy composed of two murine monoclonal antibodies, each conjugated to ricin toxin A, that specifically target CD3 and CD7 molecules on immune cells. By binding to these targets, T-Guard induces apoptosis in mature T cells (preferentially activated T cells) and natural killer (NK) cells, while also reducing T cell activation by blocking the TCR/CD3 complex. The drug is designed for rapid and transient depletion of pathogenic immune cells with the goal of resetting the immune system in life-threatening, T cell–mediated conditions such as steroid-refractory acute graft-versus-host disease (SR-aGVHD), transplant-related rejection, acute solid-organ rejection, and severe autoimmune diseases. Its short-lived action aims to minimize vulnerability to opportunistic infections compared to other therapies. Developed by Xenikos with involvement from Sanquin and clinical development support from Veloxis Pharmaceuticals, T-Guard has received Orphan Drug Designation in both the EU and US for SR-aGVHD[1][4][5][6][8].
- Brand names
- T-Guard
- Other names
- anti-CD3/CD7 ricin A immunotoxinCD3/CD7–IT
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD7 (CD7 antigen)
Beyond the preview
Go deeper on T-Guard.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-Guard.